Purpurin Suppresses Candida albicans Biofilm Formation and Hyphal Development

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Tsang, Paul Wai Kei ^a   Bandara, H M H N ^b   Fong, Wing Ping ^c  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN CONVERTING ENZYME; PURPURIN;

ALS3 GENE; ANTIFUNGAL ACTIVITY; ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; BIOFILM; CANDIDA ALBICANS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; ECE1 GENE; FUNGAL GENE; FUNGUS GROWTH; FUNGUS HYPHAE; GENE EXPRESSION; GENE IDENTIFICATION; GROWTH INHIBITION; HWP1 GENE; HYR1 GENE; IN VITRO STUDY; NONHUMAN; RAS1 GENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCANNING ELECTRON MICROSCOPY;

EID: 84870682658     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0050866     Document Type: Article

References (41)

1. Corner BE, Magee PT, (1997) Candida pathogenicity: unravelling the threads of infection. Curr Biol 7: R691-R694.
2. Wenzel RP, Gennings C, (2005) Bloodstream infections due to Candida species in the intensive care unit: identifying especially high-risk patients to determine prevention strategies. Clin Infect Dis 41: S389-S393.
3. Bustamante CI, (2005) Treatment of Candida infection: a view from the trenches! Curr Opin Infect Dis. 18: 490-495.
4. Miceli MH, Diaz JA, Lee SA, (2011) Emerging opportunistic yeast infections. Lancet Infect Dis 11: 142-151.
5. Ghannoum MA, Rice LB, (1999) Antifungal agents: mode of action, mechanisms of resistance, and correlation of these mechanisms with bacterial resistance. Clin Microbiol Rev 12: 501-507.
6. Tournu H, Serneels J, van Dijck P, (2005) Fungal pathogens research: novel and improved molecular approaches for the discovery of antifungal drug targets. Curr Drug Targets 6: 909-922.
7. Morschhäuser J, (2010) Regulation of multidrug resistance in pathogenic fungi. Fungal Genet Biol 47: 94-106.
8. Kumamoto CA, Vinces MD, (2005) Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol 7: 1546-1554.
9. Whiteway M, Bachewich C, (2007) Morphogenesis in Candida albicans. Annu Rev Microbiol 61: 529-553.
10. Cottier F, Mühlschlegel FA, (2009) Sensing the environment: Response of Candida albicans to the X factor. FEMS Microbiol Lett 295: 1-9.
11. Biswas S, van Dijck P, Datta A, (2007) Environmental sensing and signal transduction pathways regulating morphopathogenic determinants of Candida albicans. Microbiol Mol Biol Rev 71: 348-376.
12. Han TL, Cannon RD, Villas-Bôas SG, (2011) The metabolic basis of Candida albicans morphogenesis and quorum sensing. Fungal Genet Biol 48: 747-763.
13. Lo HJ, Köhler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939-949.
14. Saville SP, Lazzell AL, Monteagudo C, López-Ribot JL, (2003) Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell 2: 1053-1060.
15. Lorenz MC, Bender JA, Fink GR, (2004) Transcriptional response of Candida albicans upon internalization by macrophages. Eukaryot Cell 3: 1076-1087.
16. ten Cate JM, Klis FM, Pereira-Cenci T, Crielaard W, de Groot PW, (2009) Molecular and cellular mechanisms that lead to Candida biofilm formation. J Dent Res 88: 105-115.
17. Dongari-Bagtzoglou A, (2008) Pathogenesis of mucosal biofilms infections: challenges and progress. Expert Rev Anti Infect Ther 6: 201-208.
18. Gauwerky K, Borelli C, Korting HC, (2009) Targeting virulence: a new paradigm for antifungals. Drug Discov Today 14: 214-222.
19. Arimoto-Kobayashi S, Machida M, Okamoto K, Yamaguchi A, (2005) Evaluation of photo-mutagenicity and photo-cytotoxicity of food coloring agents. Mutagenesis 20: 229-233.
20. Kang K, Fong WP, Tsang PWK, (2010) Novel antifungal activity of purpurin against Candida species. Med Mycol 48: 904-911.
21. Liu H, Köhler J, Fink GR, (1994) Suppression of hyphal formation in Candida albicans by mutation of a STE12 homolog. Science 266: 1723-1726.
22. Bandara HMHN, Lam OLT, Watt RM, Jin LJ, Samaranayake LP, (2010) Bacterial lipopolysaccharides variably modulate in vitro biofilm formation of Candida species. J Med Microbiol 59: 1225-1234.
23. Chandra J, Mukherjee PK, Ghannoum MA, (2008) In vitro growth and analysis of Candida biofilms. Nat Protoc 3: 1909-1924.
24. Schaller M, Schäfer W, Korting HC, Hube B, (1998) Differential expression of secreted aspartyl proteinases in a model of human oral candidosis and in patient samples from the oral cavity. Mol Microbiol 29: 605-615.
25. Xie Z, Thompson A, Kashleva H, (2011) Dongari-Bagtzoglou (2011) A quantitative real-time RT-PCR assay for mature C. albicans biofilms. BMC Microbiol 11: 93.
26. Uppuluri P, Chaturvedi AK, Lopez-Ribot JL, (2009) Design of a simple model of Candida albicans biofilms formed under conditions of flow: development, architecture, and drug resistance. Mycopathologia 168: 101-109.
27. Ríos JL, Recio MC, (2005) Medicinal plants and antimicrobial activity. J Ethnopharmacol 100: 80-84.
28. Di Santo R, (2010) Natural products as antifungal agents against clinical relevant pathogens. Nat Prod Rep 27: 1084-1098.
29. Taff HT, Nett JE, Andes DR, (2012) Comparative analysis of Candida biofilms quantitation assays. Med Mycol 50: 214-218.
30. Shareck J, Nantel A, Belhumeur P, (2011) Conjugated linoleic acid inhibits hyphal growth in Candida albicans by modulating Ras1p cellular levels and downregulating TEC1 expression. Eukaryot Cell 10: 565-577.
31. Toenjes KA, Munsee SM, Ibrahim AS, Jeffrey R, Edwards JE Jr, et al. (2005) Small-molecule inhibitors of the budded-to-hyphal-form transition in the pathogenic yeast Candida albicans. Antimicrob Agents Chemother 49: 963-972.
32. Toenjes KA, Stark BC, Brooks KM, Johnson DI, (2009) Inhibitors of cellular signalling are cytotoxic or block the budded-to-hyphal transition in the pathogenic yeast Candida albicans. J Med Microbiol 58: 779-790.
33. Shareck J, Belhumeur P, (2011) Modulation of morphogenesis in Candida albicans by various small molecules. Eukaryot Cell 10: 1004-1012.
34. Kojic EM, Darouiche RO, (2004) Candida infections of medical devices. Clin Microbiol Rev 17: 255-267.
35. Finkel JS, Mitchell AP, (2011) Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9: 109-118.
36. Nobile CJ, Schneider HA, Nett JE, Sheppard DC, Filler SG, et al. (2008) Complementary adhesion function in C. albicans biofilm formation. Curr Biol 18: 1017-1024.
37. Nobile CJ, Nett JE, Andes DR, Mitchell AP, (2006) Function of Candida albicans adhesion Hwp1 in biofilms formation. Eukaryot Cell 5: 1604-1610.
38. Bailey DA, Feldmann PJ, Bovey M, Gow NA, Brown AJ, (1996) The Candida albicans HYR1 gene, which is activated in response to hyphal development, belongs to a gene family encoding yeast cell wall proteins. J Bacteriol 178: 5353-5360.
39. Luo G, Ibrahim AS, Spellberg B, Nobile CJ, Mitchell AP, et al. (2010) Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis 201: 1718-1728.
40. Luo G, Ibrahim AS, French SW, Edwards JE Jr, Fu Y, (2011) Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One 6: e25909.
41. Nobile CJ, Andes DR, Nett JE, Smith FJ, Yue F, et al. (2006) Critical role of Bcr1-dependent adhesions in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2: e63.